Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment.
Animals
Anthraquinones
/ administration & dosage
Cartilage, Articular
/ drug effects
Chemistry, Pharmaceutical
Chondroitin Sulfates
/ chemistry
Cytokines
/ drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Carriers
/ chemistry
Drug Liberation
Lipids
/ chemistry
Male
Nanoparticles
/ chemistry
Osteoarthritis
/ pathology
Oxidative Stress
/ drug effects
Particle Size
Random Allocation
Rats
Rats, Wistar
Surface Properties
Intra-articular delivery
cartilage targeting
cassic acid
chondroitin sulfate
osteoarthritis
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
24
2
2022
Statut:
ppublish
Résumé
Novel intra-articular nanoreservoirs were implemented employing different cartilage targeting approaches to improve cartilage bioavailability of a chondroprotective drug, cassic acid (CA), for effective amelioration of cartilage deterioration off-targeting CA gastrointestinal disorders. Herein, we compared active cartilage-targeting approach via chondroitin sulfate (CHS) functionalization versus passive targeting using positively charged nanoparticles to target negatively charged cartilage matrix. Firstly, CA integrated nanoreservoirs (CA-NRs) were fabricated based on ionic conjugation between CA and cationic hydrophobic surface modifier octadecylamine (ODA) and were further functionalized with CHS to develop CHS-CA-NRs. Confocal laser microscope was used to visualize the accumulation of nanoparticles into the cartilage tissue. Both targeting approaches promoted CA local cartilage availability and prolonged its residence time. Compared to passive targeted CA-NRs, active targeted CHS-CA-NRs showed higher fluorescence signals in proximity to and inside chondrocytes which lasted for up to 21 days. In MIA-osteoarthritic rats, CHS-CA-NRs showed superior antiosteoarthritic activity, exhibiting highest cartilage repair compared to CA-NRs. Additionally, CHS-CA-NRs significantly inhibited OA inflammatory cytokine, degradation enzyme and oxidative stress and improved cartilage matrix biosynthesis. Conclusively, CHS-CA-NRs improved OA repair showing a superior efficacy for articular cartilage targeting with CHS which could be a potential advance for OA therapy.
Identifiants
pubmed: 35188017
doi: 10.1080/10717544.2022.2041130
pmc: PMC8865121
doi:
Substances chimiques
Anthraquinones
0
Cytokines
0
Drug Carriers
0
Lipids
0
Chondroitin Sulfates
9007-28-7
rhein
YM64C2P6UX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
652-663Références
Food Funct. 2021 Nov 29;12(23):11732-11746
pubmed: 34698749
Int J Pharm. 2009 Oct 20;381(1):77-83
pubmed: 19647057
J Biomed Nanotechnol. 2013 May;9(5):891-900
pubmed: 23802421
Animals (Basel). 2021 May 29;11(6):
pubmed: 34072407
Nat Rev Rheumatol. 2020 Dec;16(12):673-688
pubmed: 33122845
Int J Pharm. 2016 Feb 10;498(1-2):119-29
pubmed: 26685724
Mol Pharm. 2020 Oct 5;17(10):3709-3719
pubmed: 32841038
Acta Pharmacol Sin. 2013 Aug;34(8):1108-15
pubmed: 23770990
Pharmaceutics. 2021 May 21;13(6):
pubmed: 34063749
Expert Opin Drug Deliv. 2020 Sep;17(9):1213-1226
pubmed: 32543240
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S24-34
pubmed: 20864021
Arthritis Res Ther. 2008;10(3):R71
pubmed: 18578867
Nat Biomed Eng. 2021 Sep;5(9):1069-1083
pubmed: 34413494
Int J Pharm. 2020 May 15;581:119249
pubmed: 32217157
J Orthop Res. 2021 Mar;39(3):473-484
pubmed: 32860444
Expert Opin Ther Pat. 2020 Mar;30(3):179-194
pubmed: 32003260
Nanomedicine. 2014 Jul;10(5):1031-40
pubmed: 24512762
Drug Dev Ind Pharm. 2018 Aug;44(8):1285-1294
pubmed: 29482400
Acta Biomater. 2019 Jul 15;93:239-257
pubmed: 30862551
Drug Discov Today. 2018 Oct;23(10):1761-1775
pubmed: 29792929
Osteoarthritis Cartilage. 2000 May;8(3):186-96
pubmed: 10806046
Biomed Pharmacother. 2020 Nov;131:110594
pubmed: 32858499
AMB Express. 2020 Aug 31;10(1):158
pubmed: 32865763
Osteoarthritis Cartilage. 2006 Jan;14(1):13-29
pubmed: 16242352
Nat Rev Rheumatol. 2022 Jan;18(1):35-46
pubmed: 34616035
Aging Clin Exp Res. 2021 Jan;33(1):37-47
pubmed: 32638342
Nucl Med Biol. 2013 Nov;40(8):1013-7
pubmed: 24011535
ACS Nano. 2014 Dec 23;8(12):12280-91
pubmed: 25415768
Expert Opin Ther Targets. 2018 Apr;22(4):299-318
pubmed: 29504411
Front Pharmacol. 2016 Aug 17;7:247
pubmed: 27582705
J Drug Target. 2021 Jul;29(6):609-616
pubmed: 33356642
Eur J Pharm Biopharm. 2020 Jul;152:10-17
pubmed: 32371152
Osteoarthritis Cartilage. 2021 Feb;29(2):143-150
pubmed: 33242602
Nat Prod Bioprospect. 2020 Dec;10(6):445-452
pubmed: 33128198
Biomaterials. 2021 Jan;268:120555
pubmed: 33285440
Nucl Med Biol. 2016 Jun;43(6):339-46
pubmed: 27135710
Arthritis Res Ther. 2016 Nov 3;18(1):256
pubmed: 27809891
AAPS PharmSciTech. 2021 Dec 3;23(1):9
pubmed: 34859319
J Control Release. 2021 Oct 10;338:644-661
pubmed: 34481926
Spectrochim Acta A Mol Biomol Spectrosc. 2009 Dec;74(5):1254-9
pubmed: 19857988
Int J Med Sci. 2013 Dec 21;11(1):97-105
pubmed: 24396291
J Biomech. 2007;40(8):1847-54
pubmed: 17084404
Colloids Surf B Biointerfaces. 2021 Jun;202:111713
pubmed: 33780905
Pharm Res. 2020 Jul 17;37(8):148
pubmed: 32681288
J Biomed Mater Res A. 2021 Apr;109(4):426-436
pubmed: 32780515
J Control Release. 2016 Dec 28;244(Pt A):30-40
pubmed: 27836707
Front Pharmacol. 2021 Apr 28;12:643605
pubmed: 33995052
Int J Nanomedicine. 2017 Jul 04;12:4733-4745
pubmed: 28740381
Inflammation. 2003 Aug;27(4):233-46
pubmed: 14527176
Arzneimittelforschung. 1988 May;38(5):744-8
pubmed: 3415721
Appl Radiat Isot. 2008 Apr;66(4):415-20
pubmed: 18093837
Eur J Pharm Sci. 2017 Jan 1;96:390-397
pubmed: 27721042
Int J Pharm. 2017 Nov 25;533(1):206-224
pubmed: 28943207
Chem Biol Drug Des. 2017 Nov;90(5):867-872
pubmed: 28432812
Mol Pharm. 2021 Mar 1;18(3):1444-1454
pubmed: 33538605
J Drug Target. 2014 Nov;22(9):805-12
pubmed: 24955618
Drug Deliv Transl Res. 2021 Jun;11(3):1107-1118
pubmed: 32815084
J Colloid Interface Sci. 2021 Jan 15;582(Pt B):815-824
pubmed: 32911422
Int J Pharm. 2020 Jul 30;585:119494
pubmed: 32505578
Acta Biomater. 2020 Jan 1;101:469-483
pubmed: 31586725
Drug Des Devel Ther. 2015 Apr 21;9:2301-9
pubmed: 25960633
Evid Based Complement Alternat Med. 2021 Aug 17;2021:4582412
pubmed: 34457021
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:452-456
pubmed: 28576008
J Biomech. 2009 Feb 9;42(3):286-90
pubmed: 19117573
Carbohydr Polym. 2021 Jul 1;263:117964
pubmed: 33858569